{"name":"Gamida Cell ltd","slug":"gamida-cell-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NiCord® (omidubicel)","genericName":"NiCord® (omidubicel)","slug":"nicord-omidubicel","indication":"Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia","status":"phase_3"}]}],"pipeline":[{"name":"NiCord® (omidubicel)","genericName":"NiCord® (omidubicel)","slug":"nicord-omidubicel","phase":"phase_3","mechanism":"Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation.","indications":["Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPRVVMQ1RrdVc1WFBIdkt3bUNUcTNib010SEU4azRRckdQNkRfQW90Rk5SazZQdTFTVTZYOVpvTktoc2Z2TmJwNTd3TFNPUDNpTlVqa3ppNkR4bXluYTFpenVIQTh6NGFETXJHN3JORmVzNldsZlBjd201VlZZZVVtVWR4Uk1qVktPcHZ2MmJNQzc1VHROMmhWMjF3ZmtHdUt4ai1WRkdVdU93ZThsMmtadVAydm5OUlkxdDRKRGlLZEVkaDd4TGpxbGpOQlQ0c0hKbzRBSFVaeXZaSDJWTWJjbDYtcE4?oc=5","date":"2026-02-09","type":"pipeline","source":"ACCESS Newswire","summary":"Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast Asia - ACCESS Newswire","headline":"Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPQno2aTk0Ullvam0wazh6QW9wVDIyOUQ4V1BwV3lxRVo1WlZyV1ozRFotZW10TFV2andZUS1WSEE4RlVCdHREakpqeHlUMkF4VmVuX08tVHJyRWVCcDZhZVJEcEZiYmRYNzhtN2ZoVDBTdU5xNWxjSi1iNWFGc1hnNGJYQzVPMHFtaHhFWA?oc=5","date":"2026-02-05","type":"pipeline","source":"finance.yahoo.com","summary":"Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM - finance.yahoo.com","headline":"Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Present","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQUDRBdG5ROWF3V01scDByZ3lkZzYyNUlKX3o4R2tveUNRTVhLbEhLVU10U05la0lnZWFnazdKRUJZa1RzMjlsYzI4STdqbTAzRF9tZndJUXh4U0FCRjZrdHhlTFQxZ2k3bEU2dTZad3FYYzczNDM2Z19XMi0xRTdzMW5zN1RDdG9YSVBPaWIyTzRVZmJGR3Y5V3VlTl9lV2lSOF9SOUhHeHlyT0t1ZGttUENmeUdyUl83cklJeThlM284dUhTMloxaU9td1FrYjNfVkVWeEVvMkdwSjJBcFFoWV9fU05tMjBXcGwyS3BjTnhIWVhCNFBfckxKNjlKQXRLVUxlWWpRdmFEUHFFb05IWTVwSnBvV1JZelE?oc=5","date":"2026-01-07","type":"pipeline","source":"Business Wire","summary":"RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta - Business Wire","headline":"RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPZkxPY1pxYTlrRF9nMEdOTDYxcDl2RWE5UHRxT2p5eXN3NVBVRVVpVUtWU0VOakducF9EUmdzdXIxajc2MmMtSGZBc2N4SzMzLWc4NE0ydEwycFA1VnZpVkpVNkdjR3F3ZkNRVVB5N0JSVmtSQzZabmRGeFl5R3JSSFAxWGJtektuOWY4QmhQMUhDMUM1WFA1WHBtbnlLWEx3YjN0ODYyYjJoemZtbHY0YkExSHJsenotTXhlVU80U3RuS2hTang3RzNwLVZ2eUdSemdUTG1JU0JZdDEwN3FkYU9BSVNrN0t4UmRXUkVCMU10a1hBdjFZTnNCWHNRLUNaSkU4WDQ1UVU5OUU3RHhLX0dlU09YQ3dsNXZoLUE2UzVEd25rM28wNXd6T2pIWEdNaVZMeVlwZF9jaUpkVUlrU1lyMXFCck1jVm9laTJQVQ?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge - Business Wire","headline":"RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOX0tRUmc0SGZGV0pCd1luOVI2ajNFVGFlRTRKZE03Q2ZEVnNpeVdkSlJRS0lDcFBBNW9nUHFYU3hLRXdtdmxISXRZemQ3SW1rV3kxRHFacnJTWlA5TXNvS0s4cXJIbkNScVBEYV9ORW9mNmhFWHVTWWZoZTg1Y1dzemEzNm9FeFllOFZ1bGFzWU9sd0h1SVVzZFlB?oc=5","date":"2025-03-28","type":"pipeline","source":"BioPharma Dive","summary":"Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive","headline":"Bluebird gets rival takeout offer from Ayrmid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNdVVNTm15M3JMVmFXeXVlR21nSEtuWHVtb3R4Z25sbzhrWl8wZURxSFY2ZkxSZjllSTJScF9ZNlVNRjd3b2U2c1lISGVIX2dLRmdJODZTZWEtaEZTQzAtZjQwWVNURUdBT29jQS15WUtTSVVLOFo4QURkX1BwNndXLTVEdVXSAYoBQVVfeXFMUGREdnB3XzJkUzlyWXBOVDFDQnhDNWt1dnZsMVJ2ckFqY3NNYWVWY2hpQTFvSlM0Nm5NUmxvdzVLQ3pZS0lEaE1pb2YtWWNqdnZuLUFfcWhMQXpVRVppTlFhSzN5WVMwaWtLQm9SRUQ1RHVRNER1RmRwSzJuRWFfcGpKcWxZdDFWaHhn?oc=5","date":"2025-03-20","type":"regulatory","source":"BioInformant","summary":"RoslinCT and Ayrmid Pharma Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv) - BioInformant","headline":"RoslinCT and Ayrmid Pharma Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidub","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQVWt0ZVRYR09seUZST2haQ1laYjRaTlNuYlpsanhfeGJRdlNnMW1uRjV0NWNQLWlwNEk2LVdyQ1pMWWFNZ0R3dF9IMTlrbk9QNmlKVDFZV2lqcHBtWGJVbHRiZlkwenp3cjhWYjNRMk1JMkJpSlFmUjhkQnpfa3lWSU9oSEdmODdGVFdOZk9lc3QwX1J3bU51OHlCS0ZnTmk1eS05QmJKemJtSTJvWFBOcVFSeHRfZFB4aTc3cklmdnpKWkpXbXRIcTBJWnZCWDd4ZlQxS2c2NnVQLTFDTS1TOElVaDVURlV4WUJvaFM2N1NSajF3UVZjZkJzOUstYXdWdGhfM3FhczlGdnZfVDhNTDZJVQ?oc=5","date":"2024-11-21","type":"deal","source":"PR Newswire","summary":"BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - PR Newswire","headline":"BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxObVlxc3U4MFpkUTZaMmVVWTFRVmV0dkxWei1lUF9qdTJNMGpIaTREdFJQTlZzWVBTMFJBRlF5YXpWX1k2ak5NT2J3elIwLUMtOFUtZGF1ZzFmYVIyaWd2Z3pmMzdTb1FqSjhZemdLaUlnRVQxMlRta0cyMGI0Uko5c2pwWEdUQ1ZzV1BZ0gGQAUFVX3lxTE02UWVvN05VYTI4cjVKWTlCMEtjR2hIX2IyQ1NtVTlVOTV0WTdSMzhFUDM1YnM5VDlMM2N6d052R2tPTWRvVWVXZVQ3Vk5kY05KbVNDNkZtamV3ckw3eDhmQWVKWjVHZXZDNWJMMEUwTGR5QVJJRTc5ckc0R05wNm00TWVHc3F4cm1kMmhxdmIweg?oc=5","date":"2024-11-12","type":"pipeline","source":"BioInformant","summary":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies? - BioInformant","headline":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5nN0UwZFN6SS00YWR3UUd6SkxjRHJTdjJqUi1XdmhLbS1CMmlkckFmWjFTRmhkQXRBWVBOdkpyVHowd1Zxem1QbVU5czBRLUNnTVZIMGFhVlRZa0pVY2ZJQlVhWEh2bGk1ZjBXNERFNEpveF94LWlz0gF8QVVfeXFMT0p4dzQ4bXFoMlhaLTBIMFJzVFhpS3FhQmpBX29fSThZZk9hT2hWSlZ2X2xJSDNsTjhZRXJ3bUF3Uk52NWhvUWlhbmVkRGdKTEJnSnJLdUdPY3V3R3FXMXNmbk1UM253d0k4TEN0X2lfb2VfbjJuYzJaZjFVNA?oc=5","date":"2024-08-18","type":"pipeline","source":"BioInformant","summary":"Is the CAR-T Cell Therapy Craze Driving Pharma Investment? - BioInformant","headline":"Is the CAR-T Cell Therapy Craze Driving Pharma Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQNVlhNHJ4XzBJRzJzM0JDd1AxZU9vQ181OWJfamRRUVZIbHVWTks5TlBJUzFENHprMndlaWVsYWpXZTl2ZjJWaFd6cW9pYW9tNm9Idkp0dFJBRmh4b0tVRmZjLURJSWQwWVRZRFNCaGhaRENSNUQ0bkItRWx2aTFGSFRSbnNadVdqZFlKUlptTk1TaXNOSV9WNUhUVUpyaXhDYUhSLUVQTzJzbW5VX3ZjMUtyZDByaUdyUVVtX25qUUhZelI0ZnJMRzhIZTRfdS1BTkpfMW4wS2dDQQ?oc=5","date":"2024-06-18","type":"pipeline","source":"Business Wire","summary":"Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management - Business Wire","headline":"Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1hU3pNaUpNa2tQV0t2NmlDbXNNdkZVNzU0bnFrOHdnNjNTNnc1TjN2UEhVTUV4YnoxcV9tQzJKS1RwYW1OVkRJdFBTOFhtRDYwMHEyMHlyelFLUGxKeUVn?oc=5","date":"2020-03-16","type":"pipeline","source":"ChartMill","summary":"GMDA Stock Price, Quote & Chart | GAMIDA CELL LTD (NASDAQ:GMDA) - ChartMill","headline":"GMDA Stock Price, Quote & Chart | GAMIDA CELL LTD (NASDAQ:GMDA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPUWcwMlVNb2piZlRxNjdULWNicUdHZ211NVVrdXlzVTh6WHpibkhzRGQtWEF2NWp3WGd5RE5qNGlmdDVGLXh5el9HZVVlUmhYbld1NWZsdGYzTmpELTlReWE0blgtVC1vamVfM0xwMFJlR3FkQ280NE81T0tWcWVpeHJWbzlJM0pxbzFRR29hYmYzU0E?oc=5","date":"2018-11-25","type":"pipeline","source":"Globes - Israel Business News","summary":"Teva's loss is Israeli pharma industry's gain - Globes - Israel Business News","headline":"Teva's loss is Israeli pharma industry's gain - Globes","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}